生物产业技术Issue(1)：28-30,3.DOI:10.3969/j.issn.1674-0319.2017.01.004
香雪生命科学：为中国生物治疗助力
XLifeSc:boost up biological therapies in China
许永村 1冯春明1
作者信息
- 1. 香雪生命科学研究中心，广州 510663
- 折叠
摘要
Abstract
Due to the extended life expectancy of humans and the deteriorating living conditions, especially for air and water pollutions caused by over-industrialization and urbanization, malignant tumors have become a common threat to human health. The incidence rate is rising significantly year after year and the number of deaths is about one quarter of all disease types. Today, malignant tumor is listed as the“number one killer”of humans and considered to be a great challenge worldwide. Founded in September 2012, Guangzhou Xiangxue Life Sciences Research Cen-ter focuses on the development of biological immunotherapy for treating malignant tumors that are refractory to con-ventional treatments. Its product lines include tumor antigen specific biologicals and T cell therapy. Both innovative agents provide truly feasible measures to accomplish the goal of curing tumors.关键词
细胞免疫治疗/癌症/T细胞受体Key words
cellular immunotherapy/cancer/T cell receptor引用本文复制引用
许永村,冯春明..香雪生命科学：为中国生物治疗助力[J].生物产业技术,2017,(1):28-30,3.
